Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
